Navigation

Aredia

Aredia - General Information

Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia, is a bisphosphonate. [Wikipedia]

 

Pharmacology of Aredia

Aredia is in a class of drugs called bisphosphonates. Aredia reduces breakdown of the bones. Aredia is used in the treatment of Paget's disease of bone; to reduce high levels of calcium in the blood associated with malignancy (cancer); and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma.

 

Aredia for patients

 

Aredia Interactions

Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of Aredia.

Caution is indicated when Aredia is used with other potentially nephrotoxic drugs.

Also see CLINICAL PHARMACOLOGY

 

Aredia Contraindications

Aredia is contraindicated in patients with clinically significant hypersensitivity to Aredia or other bisphosphonates.

 

Additional information about Aredia

Aredia Indication: For the treatment of moderate or severe hypercalcemia associated with malignancy
Mechanism Of Action: The mechanism of action of pamidronate is inhibition of bone resorption. Aredia adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. Aredia also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Pamidronate
Synonyms: Acide pamidronique [INN-French]; Acido pamidronico [INN-Spanish]; Acidum pamidronicum [INN-Latin]; APD; Pamidronate Disodium; Pamidronic acid
Drug Category: Anti-inflammatory Agents; Antineoplastic Agents; Bisphosphonates
Drug Type: Small Molecule; Approved
Other Brand Names containing Pamidronate: Amidronate; Aminomux; Aredia;
Absorption: Not Available
Toxicity (Overdose): Side effects include an allergic reaction, kidney problems, seizures, low levels of calcium, magnesium, or phosphorus in the blood
Protein Binding: Approximately 54% (bound to human serum proteins)
Biotransformation: Pamidronate is not metabolized and is exclusively eliminated by renal excretion
Half Life: The mean ± SD elimination half-life is 28 ± 7 hours
Dosage Forms of Aredia: Solution Intravenous
Powder, for solution Intravenous
Chemical IUPAC Name: (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid
Chemical Formula: C3H11NO7P2
Pamidronate on Wikipedia: http://en.wikipedia.org/wiki/Pamidronate
Organisms Affected: Humans and other mammals